Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775631 · ClinicalTrials.gov registry record · Phase 1
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01775631 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 47 participants.
The verdict
NCT01775631, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma
Interventions
- BIOLOGICAL Rituximab
- BIOLOGICAL Urelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775631
The ClinicalTrials.gov registry entry for NCT01775631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01775631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01775631 about?
NCT01775631 is a clinical study titled "Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma". The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma
What is the current status of trial NCT01775631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2013-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01775631?
The interventions under investigation include: Rituximab (BIOLOGICAL), Urelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01775631?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.